[Aldosterone: mechanisms of normal and impaired regulation and the possibility of their correction in arterial hypertension. Consensus of Russian Medical Society on Arterial Hypertension (RSH) experts].
NM, C., NV, B., OI, T., VI, P., AE, B., & IE, C. (2026). [Aldosterone: mechanisms of normal and impaired regulation and the possibility of their correction in arterial hypertension. Consensus of Russian Medical Society on Arterial Hypertension (RSH) experts].. Terapevticheskii arkhiv. https://doi.org/10.26442/00403660.2026.07.203747
NM C, NV B, OI T, VI P, AE B, IE C. [Aldosterone: mechanisms of normal and impaired regulation and the possibility of their correction in arterial hypertension. Consensus of Russian Medical Society on Arterial Hypertension (RSH) experts].. Terapevticheskii arkhiv. 2026; doi: 10.26442/00403660.2026.07.203747
NM C, NV B, OI T, et al. [Aldosterone: mechanisms of normal and impaired regulation and the possibility of their correction in arterial hypertension. Consensus of Russian Medical Society on Arterial Hypertension (RSH) experts].[J]. Terapevticheskii arkhiv. 2026. DOI: 10.26442/00403660.2026.07.203747.
@article{nm2026,
author = {Chikhladze NM and Blinova NV and Trushina OI and Podzolkov VI and Bragina AE and Chazova IE},
title = {[Aldosterone: mechanisms of normal and impaired regulation and the possibility of their correction in arterial hypertension. Consensus of Russian Medical Society on Arterial Hypertension (RSH) experts].},
journal = {Terapevticheskii arkhiv},
year = {2026},
doi = {10.26442/00403660.2026.07.203747},
note = {PMID: 42615817},
}
TY - JOUR AU - Chikhladze NM AU - Blinova NV AU - Trushina OI AU - Podzolkov VI AU - Bragina AE AU - Chazova IE TI - [Aldosterone: mechanisms of normal and impaired regulation and the possibility of their correction in arterial hypertension. Consensus of Russian Medical Society on Arterial Hypertension (RSH) experts]. T2 - Terapevticheskii arkhiv PY - 2026 DO - 10.26442/00403660.2026.07.203747 AN - PMID:42615817 ER -
In recent years, studies have been carried out that have expanded the understanding of the role of pathophysiological mechanisms underlying impaired regulation of aldosterone and activation of mineralocorticoid receptors in arterial hypertension. The aim of this consensus is to consider the association between aldosterone dysregulation and the development of cardiovascular complications, as well as to assess the effectivity and safety of novel nonsteroidal mineralocorticoid receptor antagonists, to expand the understanding of their potential in ensuring the prevention of target organ damage and cardiovascular complications in the treatment of patients with hypertension, to analyze the potential of a new class of drugs - aldosterone synthase inhibitors - in ensuring the suppression of genomic and non-genomic effects of aldosterone and their adverse effects in patients with hypertension, to assess the efficacy of drug therapy including nonsteroidal mineralocorticoid receptor antagonists and aldosterone synthase inhibitors in the category of patients at high cardiovascular risk - in hypertension due to primary hyperaldosteronism. В последние годы проведены исследования, которые расширили представление о роли патофизиологических механизмов, лежащих в основе нарушенной регуляции альдостерона и активации минералокортикоидных рецепторов (МКР) при артериальной гипертонии (АГ). Цель консенсуса – рассмотреть связь между дисрегуляцией альдостерона и развитием сердечно-сосудистых осложнений, оценить эффективность и безопасность новых нестероидных антагонистов МКР, расширить представление об их возможности в обеспечении профилактики поражения органов-мишеней и сердечно-сосудистых осложнений при лечении пациентов с АГ, проанализировать потенциал нового класса препаратов – ингибиторов альдостеронсинтазы – в обеспечении подавления геномных и негеномных эффектов альдостерона и их неблагоприятных последствий у пациентов с АГ, исследовать эффективность медикаментозной терапии, включающей нестероидные антагонисты МКР и ингибиторы альдостеронсинтазы, у категории пациентов высокого сердечно-сосудистого риска – при АГ, обусловленной первичным гиперальдостеронизмом.